 LA JOLLA, Calif., March 09, 2021 GLOBE NEWSWIRE -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market NASDAQ:MNOV and the JASDAQ Market of the Tokyo Stock Exchange Code Number: 4875, today announced it has partnered with the Biomedical Advanced Research and Development Authority BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to repurpose MN-166 ibudilast as a potential medical countermeasure MCM against chlorine gas-induced lung damage such as acute respiratory distress syndrome ARDS and acute lung injury ALI. Under the Division of Research, Innovation, and Ventures DRIVe Repurposing Drugs in Response to Chemical Threats ReDIRECT program, BARDA will provide funding for proof-of-concept studies of MN-166 in preclinical models of chlorine gas-induced acute lung injury. MN-166 is the first compound to receive BARDAs development support through the DRIVe ReDIRECT program. 